|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Prostatic Neoplasms | |||||
| Fatigue | |||||
| 2 | More general conditions related to this trial | ||||
| Genital Diseases, Male | |||||
| Genital Neoplasms, Male | |||||
| Neoplasms | |||||
| Neoplasms by Site | |||||
| Prostatic Diseases | |||||
| Signs and Symptoms | |||||
| Urogenital Neoplasms | |||||
| 3 | Interventions listed in this trial | ||||
| Methylphenidate Hydrochloride | |||||
| Matched Placebo | |||||
| 4 | Additional drug interventions recognized in this trial | ||||
| Methylphenidate | |||||
| 5 | More general drug interventions related to this trial | ||||
| Central Nervous System Agents | |||||
| Central Nervous System Stimulants | |||||
| Dopamine Agents | |||||
| Dopamine Uptake Inhibitors | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Neurotransmitter Agents | |||||
| Neurotransmitter Uptake Inhibitors | |||||
| Pharmacologic Actions | |||||
| Physiological Effects of Drugs | |||||
| Therapeutic Uses | |||||
| 6 | Sponsors listed in this trial | ||||
| University Health Network, Toronto | |||||
| Sanofi-Aventis | |||||